Entrada Therapeutics (TRDA) Operating Leases (2022 - 2026)

Entrada Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $45.5 million for Q1 2026.

• In Q1 2026, Operating Leases fell 9.94% year-over-year to $45.5 million; the TTM figure through Mar 2026 stood at $45.5 million (down 9.94% YoY), while the FY2025 annual figure was $46.8 million, down 9.4% from the prior year.
• Operating Leases for Q1 2026 stood at $45.5 million, down from $46.8 million in the prior quarter.
• The five-year high for Operating Leases was $73.0 million in Q2 2023, with the low at $16.2 million in Q1 2023.
• The 5-year median for Operating Leases is $49.3 million (2025), against an average of $45.7 million.
• The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 49.07% in 2023, then jumped 258.28% in 2024.
• Entrada Therapeutics' Operating Leases stood at $17.5 million in 2022, then jumped by 244.1% to $60.3 million in 2023, then dropped by 14.38% to $51.6 million in 2024, then dropped by 9.4% to $46.8 million in 2025, then declined by 2.83% to $45.5 million in 2026.
• Business Quant data shows TRDA's Operating Leases at $45.5 million in Q1 2026, $46.8 million in Q4 2025, and $48.0 million in Q3 2025.